Chuqing Cao1,2, Shuting Yang1,2, Zhiguang Zhou3,4. 1. Department of Metabolism & Endocrinology, The Second Xiangya Hospital, Central South University, No. 139 Renmin Road, Changsha, 410011, Hunan, China. 2. Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, China. 3. Department of Metabolism & Endocrinology, The Second Xiangya Hospital, Central South University, No. 139 Renmin Road, Changsha, 410011, Hunan, China. zhouzhiguang@csu.edu.cn. 4. Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, China. zhouzhiguang@csu.edu.cn.
Abstract
PURPOSE: Some preliminary studies reported a link between GLP-1 receptor agonists (GLP-1RAs) and thyroid/pancreatic neoplasms, while its human relevance remained undetermined. The present meta-analysis was performed to collect information on cancers associated with GLP-1RAs in patients with type 2 diabetes mellitus (T2DM). METHODS: Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and ClinicalTrials.gov were extensively searched to identify randomized controlled trials that reported cancer events in T2DM patients treated with GLP-1RAs for at least 52 weeks, up to March 18, 2019. Odds ratio (OR) with 95% Confidence Interval (CI) was calculated for overall cancer (primary outcome), thyroid and pancreatic cancer. RESULTS: A total of 37 eligible trials were identified. The OR for overall cancer associated with GLP-1RAs was 1.03 (95% CI 0.95-1.12; p = 0.41) compared with comparators. Subgroup analyses showed that treatment with albiglutide was associated with a lower risk of overall cancer (OR 0.76 [95% CI 0.60-0.97]; p = 0.03), and no elevated risk of overall cancer was identified for other GLP-1RAs. No significant differences in the risks of thyroid nor pancreatic cancer were disclosed between GLP-1RAs and comparators. CONCLUSIONS: This meta-analysis did not suggest any increased risk of cancers associated with GLP-1RAs use in T2DM. The reduction in the risk of overall cancer associated with albiglutide needs to be examined further.
PURPOSE: Some preliminary studies reported a link between GLP-1 receptor agonists (GLP-1RAs) and thyroid/pancreatic neoplasms, while its human relevance remained undetermined. The present meta-analysis was performed to collect information on cancers associated with GLP-1RAs in patients with type 2 diabetes mellitus (T2DM). METHODS: Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and ClinicalTrials.gov were extensively searched to identify randomized controlled trials that reported cancer events in T2DM patients treated with GLP-1RAs for at least 52 weeks, up to March 18, 2019. Odds ratio (OR) with 95% Confidence Interval (CI) was calculated for overall cancer (primary outcome), thyroid and pancreatic cancer. RESULTS: A total of 37 eligible trials were identified. The OR for overall cancer associated with GLP-1RAs was 1.03 (95% CI 0.95-1.12; p = 0.41) compared with comparators. Subgroup analyses showed that treatment with albiglutide was associated with a lower risk of overall cancer (OR 0.76 [95% CI 0.60-0.97]; p = 0.03), and no elevated risk of overall cancer was identified for other GLP-1RAs. No significant differences in the risks of thyroid nor pancreatic cancer were disclosed between GLP-1RAs and comparators. CONCLUSIONS: This meta-analysis did not suggest any increased risk of cancers associated with GLP-1RAs use in T2DM. The reduction in the risk of overall cancer associated with albiglutide needs to be examined further.
Authors: Xavier Michelet; Lydia Dyck; Andrew Hogan; Roisin M Loftus; Danielle Duquette; Kevin Wei; Semir Beyaz; Ali Tavakkoli; Cathriona Foley; Raymond Donnelly; Cliona O'Farrelly; Mathilde Raverdeau; Ashley Vernon; William Pettee; Donal O'Shea; Barbara S Nikolajczyk; Kingston H G Mills; Michael B Brenner; David Finlay; Lydia Lynch Journal: Nat Immunol Date: 2018-11-12 Impact factor: 25.606
Authors: Baptist Gallwitz; Juan Guzman; Francesco Dotta; Bruno Guerci; Rafael Simó; Bruce R Basson; Andreas Festa; Jacek Kiljański; Hélène Sapin; Michael Trautmann; Guntram Schernthaner Journal: Lancet Date: 2012-06-09 Impact factor: 79.321
Authors: Serge A Jabbour; Juan P Frías; Elise Hardy; Azazuddin Ahmed; Hui Wang; Peter Öhman; Cristian Guja Journal: Diabetes Care Date: 2018-08-06 Impact factor: 19.112
Authors: Michaela Diamant; Luc Van Gaal; Bruno Guerci; Stephen Stranks; Jenny Han; Jaret Malloy; Marilyn K Boardman; Michael E Trautmann Journal: Lancet Diabetes Endocrinol Date: 2014-04-04 Impact factor: 32.069
Authors: Adrian F Hernandez; Jennifer B Green; Salim Janmohamed; Ralph B D'Agostino; Christopher B Granger; Nigel P Jones; Lawrence A Leiter; Anne E Rosenberg; Kristina N Sigmon; Matthew C Somerville; Karl M Thorpe; John J V McMurray; Stefano Del Prato Journal: Lancet Date: 2018-10-02 Impact factor: 79.321
Authors: Alexandra E Butler; Martha Campbell-Thompson; Tatyana Gurlo; David W Dawson; Mark Atkinson; Peter C Butler Journal: Diabetes Date: 2013-03-22 Impact factor: 9.461
Authors: Raymond Ngai Chiu Chan; Teddy Tai Loy Lee; Oscar Hou In Chou; Jenny So; Cheuk To Chung; Edward Christopher Dee; Kenrick Ng; Pias Tang; Leonardo Roever; Tong Liu; Wing Tak Wong; Gary Tse; Sharen Lee Journal: J Endocr Soc Date: 2022-09-05